Our results indicate that denosumab treatment and OPG overexpression suppressed dTHP-1 activity by inhibiting these signaling pathways through which TAM can be polarized to the M2 (pro-tumoral) phenotype to contribute to tumor progression37–41. This evidence concerns the gene TNFRSF11B and neoplasm.